Login to Your Account



FDA Panel Not Impressed By TKT's Replagal Presentation

By Kim Coghill


Wednesday, January 15, 2003
Incomplete data and a failure to show statistically significant outcomes in clinical studies put Transkaryotic Therapies Inc. in the unenviable spot of trying to justify its application for Replagal to an FDA advisory panel Tuesday. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription